EP Patent

EP1506193B3 — Carbamat-substituierte pyrazolopyridine

Assigned to Bayer Intellectual Property GmbH · Expires 2025-12-03 · 0y expired

What this patent protects

Patent listed against Adempas.

Drugs covered by this patent

Adempas (RIOCIGUAT) · Bayer

Patent Metadata

Patent number: EP1506193B3
Jurisdiction: EP
Classification: —
Expires: 2025-12-03
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Intellectual Property GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.